| Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03735589) | Roswell Park Cancer Institute | 2023-12-15 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer (NCT05415709) | Ohio State University Comprehensive Cancer Center | 2022-06-13 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801) | M.D. Anderson Cancer Center | 2021-09-30 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (NCT04329494) | City of Hope Medical Center | 2020-08-21 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (NCT04575935) | M.D. Anderson Cancer Center | 2020-08-05 |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer (NCT04794322) | Massachusetts General Hospital | 2020-04-13 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913) | City of Hope Medical Center | 2019-12-24 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers (NCT03968406) | M.D. Anderson Cancer Center | 2019-09-26 |
| A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (NCT03784677) | M.D. Anderson Cancer Center | 2019-07-29 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery (NCT03943173) | M.D. Anderson Cancer Center | 2019-06-07 |
| Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer (NCT04067960) | Mayo Clinic | 2019-06-06 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527) | Precigen, Inc | 2019-04-30 |
| Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer (NCT03606486) | University of Washington | 2018-11-16 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis (NCT03508570) | M.D. Anderson Cancer Center | 2018-09-21 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability (NCT03428802) | Rutgers, The State University of New Jersey | 2018-03-08 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |